Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on ASND stock, giving a Buy rating on November 24.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tazeen Ahmad has given his Buy rating due to a combination of factors related to Ascendis Pharma’s strategic developments and regulatory progress. Despite the extension of the PDUFA date for TransCon CNP, a treatment for achondroplasia, to February 28, 2026, Ahmad sees no adverse impact on the likelihood of its approval. The delay was attributed to a major amendment regarding post-marketing commitments, with no concerns raised by the FDA about the clinical data or manufacturing processes.
Ahmad interprets the extension as a broader trend of delayed PDUFA dates due to minor issues, rather than a reflection of any significant problem with Ascendis Pharma’s submission. Consequently, he maintains a positive outlook on the company’s prospects, keeping the Buy rating and a price objective of $242, as the anticipated early 2026 launch remains unchanged in his financial model.
According to TipRanks, Ahmad is a 3-star analyst with an average return of 2.3% and a 53.56% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Incyte, and BioNTech SE.
In another report released on November 24, Morgan Stanley also maintained a Buy rating on the stock with a $250.00 price target.